RESOURCE USE AND ASSOCIATED COSTS FOR METASTATIC SQUAMOUS NON SMALL CELL LUNG CANCER (SQ NSCLC) PATIENTS: A RETROSPECTIVE CHART REVIEW IN SELECT EUROPEAN COUNTRIES

被引：0
|
作者：
Lorenzo, M. [1 ]
Brown, J. [1 ]
Kurosky, S. [2 ]
Ajmera, M. R. [2 ]
Kaye, J. A. [3 ]
机构：
[1] Eli Lilly & Co Ltd, Windlesham, Surrey, England
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] RTI Hlth Solut, Waltham, MA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2333
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN257
引用
收藏
页码：A755 / A755
页数：1
相关论文
共 50 条
  • [21] SYSTEMATIC LITERATURE REVIEW OF TREATMENTS FOR PATIENTS WITH UNTREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
    Song, J.
    Huang, M.
    Kelkar, S. S.
    Zhou, Z.
    Zhang, Y.
    VALUE IN HEALTH, 2018, 21 : S15 - S16
  • [22] Sitravatinib plus tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
    Zhou, Q.
    Yu, X.
    Gao, B.
    Ma, Z.
    Chu, Q.
    Huang, D.
    Zhao, J.
    Day, D.
    Body, A. L.
    Pan, H.
    Cui, J.
    Chen, C.
    Xiang, X.
    Fei, C.
    Yang, L.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2021, 32 : S996 - S997
  • [23] Sarcopenia as a marker of outcome in patients with metastatic non-small cell lung cancer: A retrospective review.
    Khandelwal, Keerti Munnalal
    Prevegliano, Carlos
    Shi, Runhua
    Sangster, Guillermo
    Gonzalez, Eduardo Toledo
    Jafrl, Syed Hasan Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence
    Lim, Joline S. J.
    Soo, Ross A.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (05) : 444 - 454
  • [25] Management and treatment costs of non-squamous metastatic or locally advanced non-small cell lung cancer
    Pruszko, Cezary
    Jachimowicz, Michal
    Kalinowska, Agnieszka
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 (02): : 63 - 67
  • [26] Comment on the work Methods and costs of non squamous metastatic or locally advanced non small cell lung cancer treatment
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 (02): : 68 - 68
  • [27] Management and outcomes of patients with non small cell lung cancer (NSCLC) and synchronous brain metastases: A multicentre retrospective review
    Cook, M.
    Allos, B.
    O'Beirn, M.
    Denley, S.
    Homer, K.
    Sabel, L.
    Jegannathen, A.
    Chatterjee, A.
    Koh, P.
    LUNG CANCER, 2017, 103 : S12 - S12
  • [28] RESOURCE UTILIZATION AMONG ADVANCED SQUAMOUS AND NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING SECOND-LINE TREATMENT IN FRANCE, GERMANY, ITALY, AND SPAIN: RESULTS OF A RETROSPECTIVE MEDICAL CHART REVIEW
    Solem, C. T.
    Penrod, J. R.
    Lees, M.
    Daumont, Manley M.
    Macahilig, C. P.
    Baeten, S.
    Verleger, K.
    Wilke, T.
    VALUE IN HEALTH, 2015, 18 (07) : A450 - A450
  • [29] AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)
    Yu, Y.
    Huang, D.
    Gao, B.
    Zhao, J.
    Hu, Y.
    Zhuang, W.
    Kao, S.
    Xu, W.
    Yao, Y.
    Yang, T-Y.
    Lee, Y.
    Kim, J-S.
    Shiah, H-S.
    Wang, R.
    Zheng, H.
    Tan, W.
    Gao, R.
    Kim, H. R.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1019 - S1019
  • [30] A REVIEW OF ETOPOSIDE IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER (NSCLC)
    ITRI, LM
    GRALLA, RJ
    CANCER TREATMENT REVIEWS, 1982, 9 : 115 - 118
12345